JUN 16, 2021 7:00 AM PDT

Researchers Identify a Novel COVID Therapeutic Target and Mortality Predictor

WRITTEN BY: Tara Fernandes

Researchers at King’s College London have discovered a new antiviral target to combat COVID-19: the galectin-3-binding protein, or LGALS3BP. 

Analysis of around 500 blood samples from COVID-19 patients admitted to the intensive care unit revealed that during infection, LGALS3BP levels in the lungs were significantly elevated. The scientists found that the interaction between the SARS-CoV-2 spike protein and LGALS3BP may be a novel therapeutic target to help alleviate the life-threatening symptoms of COVID-19.

Additionally, the researchers found that the presence of SARS-CoV-2 RNA in the blood of COVID-19 patients could be used as a predictive mortality marker. 56 percent of ICU patients who had succumbed to severe COVID-19 symptoms had detectable viral RNA in the blood, compared to just 13 percent of those who survived the infection.

"We report that presence of detectable viral RNA in plasma or serum of COVID-19 patients is associated with increased risk of severe illness. We also highlight a novel interaction with potential antiviral effect between the SARS-CoV-2 spike protein and a protein called galectin-3-binding protein,” said Manu Shankar Hari, who led the research. 

“Our research findings have two main implications. First, there is an unmet diagnostic technology need for near patient tests to identify the presence of viral RNA in blood in COVID-19 patients. Second, our research potentially highlights an antiviral drug target, which is a priority area highlighted within the UK government's launch of a COVID-19 antivirals Taskforce."

 


Sources: Nature Communications, King's College London.

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
MAY 15, 2022
Health & Medicine
Virus-Infected Pig Heart Transplanted Into a Human
MAY 15, 2022
Virus-Infected Pig Heart Transplanted Into a Human
The University of Maryland School of Medicine reached a medical milestone this year when it transplanted a genetically-e ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 10, 2022
Immunology
Is Autoimmunity Related to Schizophrenia?
JUN 10, 2022
Is Autoimmunity Related to Schizophrenia?
Schizophrenia is estimated to impact around 24 million people, which is about 1 in 300 people worldwide. This poorly und ...
JUN 10, 2022
Health & Medicine
What's Being Done to Make COVID Vaccines More Effective Against Future Strains?
JUN 10, 2022
What's Being Done to Make COVID Vaccines More Effective Against Future Strains?
Were you boosted, got Omicron, and still felt like death warmed over twice? It happens, and it’s no secret th ...
AUG 01, 2022
Cell & Molecular Biology
Gut Microbes that Release Histamine Worsen IBS Pain
AUG 01, 2022
Gut Microbes that Release Histamine Worsen IBS Pain
When the white blood cells in our bodies encounter a pathogen, they can release a molecule called histamine, which can h ...
AUG 16, 2022
Immunology
Two Studies Describe Powerful Antibodies That Neutralize SARS-CoV-2
AUG 16, 2022
Two Studies Describe Powerful Antibodies That Neutralize SARS-CoV-2
SARS-CoV-2, which causes COVID-19, has mutated many times into new variants, some that we don't hear about, while others ...
Loading Comments...